

## APPLICATION OF ACQUITY TQD FOR THE ANALYSIS OF CHLORAMPHENICOL RESIDUES IN HONEY EXTRACTS

James Morphet and Peter Hancock, Waters Corporation, Manchester, UK

### OVERVIEW

This application note will evaluate the suitability of the Waters® ACQUITY® TQD for tandem quadrupole based analysis of chloramphenicol with its deuterated internal standard using Multiple Reaction Monitoring (MRM) experiments. Honey extracts will be used for this analysis.

### INTRODUCTION

Chloramphenicol is used by beekeepers to control American Foulbrood Disease within hives which is believed to be caused by *Paenibacillus* larvae. See Figure 1. This is used even though there are no approved antibiotic treatments for American Foulbrood.

Concern with antibiotic therapies is that they may remove the symptoms but a low level of the bacteria may persist, and can then be spread to otherwise healthy hives. Chloramphenicol is a potent antibiotic that may eliminate the disease in hives. It had been in worldwide use before being widely withdrawn due to restrictions upon its entry into food products<sup>1</sup>. Residues of chloramphenicol can be found in honey if bees are treated during the harvesting season<sup>2</sup>.

The current EU legislation that governs chloramphenicol is EU decision 2003/181/EC<sup>3</sup>. A Minimum Required Performance Limit (MRPL) has been set at 0.3 µg/kg for honey as it falls into the category of animal derived food. The Japanese Positive List<sup>4</sup> and FDA<sup>5</sup> both state that chloramphenicol should not be present in honey and it is banned from food in both countries.




Figure 1. Chloramphenicol molecule.



Figure 2. ACQUITY TQD featuring the TQ Detector.

The MRPL is the target for laboratories with the least sensitive analytical techniques. Achieving and going below this level will lead to an increase in food safety as contaminated batches which do not meet the relevant regulations can be destroyed.

Chloramphenicol toxicity in humans has a wide range of effects. Bone marrow depression is common but the effects can be reversed if levels in the body are lowered or eliminated. Aplastic anemia gives a more serious reaction which is not considered to be dose related. It has a frequency of one incidence in every 24,000-40,000 courses of treatment, with a mortality rate greater than 50% of cases<sup>6</sup>.

The introduction of the ACQUITY TQD detector allows scientists to perform chloramphenicol analysis while harnessing all the benefits that this instrument brings to the laboratory. See Figure 2. The IntelliStart™ technology in this instrument is designed to reduce the burden of complicated operation, time-intensive troubleshooting, and upkeep. Its small footprint will give any laboratory an advantage as this powerful tool removes the need for larger instrumentation.

This note describes chloramphenicol analysis, using a solution which is able to exceed the requirements of worldwide regulation, the lowest level being the current EU legislation.

## EXPERIMENTAL

Blank honey extracts and solvent solutions of chloramphenicol and deuterated chloramphenicol (internal standard) were kindly provided by the Central Science Laboratory, (CSL) York, UK. This CSL procedure involves an overall 2x dilution during the extraction from honey to in-vial sample. Samples for analysis were prepared by spiking the blank extract at varying concentrations to achieve a matrix matched calibration curve.

## UPLC CONDITIONS

LC system:	Waters ACQUITY UPLC® System		
Column:	ACQUITY UPLC BEH C <sub>18</sub> Column		
	2.1 x 50 mm, 1.7 µm		
Column temp:	30 °C		
Flow rate:	450 µL/min.		
Mobile phase A:	98:2 (v/v) water: methanol		
Mobile phase B:	Methanol		
Gradient:	Time	0.00 min	95% A
	Time	0.50 min	95% A
	Time	1.60 min	10% A
	Time	1.90 min	10% A
	Time	2.05 min	95% A
Total run time	3.5 min		
Injection volume	20 µL, Full loop injection		

## MS CONDITIONS

MS system:	Waters ACQUITY TQ Detector		
Ionization mode:	ESI negative polarity		
Capillary voltage:	3 kV		
Cone voltage:	30 V		
Desolvation gas:	Nitrogen, 800 L/Hr, 450 °C		
Cone gas:	Nitrogen, 20 L/Hr		
Source temp:	120 °C		
Acquisition:	Multiple Reaction Monitoring (MRM)		
Collision gas:	Argon at $3.5 \times 10^{-3}$ mBar		

## Acquisition and Processing Methods

The data were acquired using Waters MassLynx™ Software v. 4.1. Incorporated into MassLynx is the IntelliStart technology which was designed specifically for the SQ and TQ detectors. IntelliStart automates optimization of MS parameters for your sample and also monitors the health of the MS system, reducing the time for operator-intensive troubleshooting and upkeep. The data was processed using TargetLynx™ Application Manager. This quantification package is capable of automating quality control checks such as calculating ion ratios, flagging analytical results above/below thresholds set by the user, plus other features.

## RESULTS AND DISCUSSION

Chloramphenicol was chromatographed successfully. Figure 3 shows chloramphenicol and its internal standard at a concentration equivalent to ten times below the MRPL – 0.03 µg/kg in matrix. This gives a signal to noise figure of 55:1, peak to peak. The ACQUITY UPLC® method described gives a retention time of 1.66 minutes for chloramphenicol.




Figure 3. Chloramphenicol in honey matrix ten times below the MRPL at 0.03 µg/kg.

# [APPLICATION NOTE]




Figure 4. TargetLynx screenshot showing linear range of chloramphenicol in honey matrix (0.015 pg/μL to 3 pg/μL equivalent to 0.03 μg/kg to 6 μg/kg in pre-extracted honey).

Figure 4 shows the linearity of the ACQUITY TQD. Here the quantifiable range is from 0.015 pg/μL to 3 pg/μL equivalent to 0.03 μg/kg to 6 μg/kg in pre extracted honey. This calibration curve shows good linearity with a correlation coefficient of  $r^2 > 0.999$ . The variance between the calibration points in the line is within acceptable values as all points lie within 15% of their nominal value. The linear range achieved with this assay is equivalent to 0.03 μg/kg to 6 μg/kg in honey.

The low point of the calibration curve allows quantitation to ten times below the MRPL. A further increase in sensitivity can be achieved using ACQUITY TQD by injecting more sample onto the column or modifying the sample extraction method. The extraction used includes an overall dilution of 2 resulting in a matrix equivalent of 0.5 g/mL. A sample concentration step would give lower levels of quantitation with this instrument.

Instrument ruggedness was tested using multiple injections of matrix-matched standard at the MRPL level. The amount of matrix injected onto column was 700 mg when seventy injections were made in succession.

The plot of peak area against injection number shows that there is no drop off in response when considering the analyte peak area

only. See Figure 5. The percent relative standard deviation (%RSD) is shown in the header of the graph and is 5.1% over the 70 injection run.




Figure 5. Plot showing changes in chloramphenicol peak area over a 70 injection run. The amount of compound injected onto the column from the sample extract is equivalent to the MRPL level of 0.3 μg/kg in honey.

The response ratio was also measured over the run (analyte peak area/internal standard peak area). Figure 6 shows a similar pattern to Figure 5 with regard to outliers and overall %RSD. This shows that this assay can be run either with or without internal standard but will give better results when it is included.




Figure 6. Plot showing changes in chloramphenicol response ratio over a 70 injection run. The amount of compound injected onto the column from the sample extract is equivalent to the MRPL level of 0.3 μg/kg in honey.

Ion ratio stability was also assessed. The average difference is 7%. Figure 7 shows this plot with the mean value highlighted as a red line. All injections lie within a 20% tolerance limit as specified in EU legislation 2002/657/EC<sup>7</sup>.




Figure 7. Plot showing changes in chloramphenicol ion ratio over a 70 injection run. The amount of compound injected onto the column from the sample extract is equivalent to the MRPL level of 0.3 µg/kg in honey.

## CONCLUSION

A method based on ACQUITY TQD was developed for the analysis of chloramphenicol in honey extract.

Chloramphenicol, which causes serious harm to human health, can be quantified in honey matrix using the method described at levels below the EU legislation limits with ACQUITY TQD.

ACQUITY TQD response remained constant throughout a run of 70 samples with a tight RSD of 5.1%.

Ion ratios for confirmation using two MRM transitions were shown to be stable which is important for quantification and confirmation.

The benefits of UPLC® for a revenue conscious laboratory are shown with increased speed, along with reduced solvent usage and the associated costs of solvents and solvent disposal.



## Acknowledgements

The authors would like to thank Richard Fussell and Michael Dickinson at the Central Science Laboratory (CSL), Sand Hutton, York, UK for kindly supplying the sample extracts and standard solutions that were analyzed in this project.

## References

1. Institute for Traditional Medicine web site: <http://www.itmonline.org/arts/bees.htm>
2. Verzeznassi, L, Royer, D, Mottier, P, and Stadler, R H, Food Addit. Contam. 20 (2003) 335-342.
3. EU Directive 2003/181/EC online: [http://eurlex.europa.eu/LexUriServ/site/en/oj/2003/l\\_071l\\_07120030315en00170018.pdf](http://eurlex.europa.eu/LexUriServ/site/en/oj/2003/l_071l_07120030315en00170018.pdf)
4. The Japanese Positive List online: <http://www.ffcr.or.jp/zaidan/FFCRHOME.nsf/pages/MRLs-p>
5. The US Food and Drug Administration web site: <http://www.fda.gov/>
6. Toxicological Evaluation of Certain Veterinary Drug Residues in Food, International Program on Chemical Safety, World Health Organization.
7. Commission Directive 2002/657/EC, Off. J. of the European Communities No. L221/8.

# Waters

THE SCIENCE OF WHAT'S POSSIBLE.™

Waters, ACQUITY, ACQUITY UPLC, and UPLC are registered trademarks of Waters Corporation. IntelliStart, MassLynx, TargetLynx, and The Science of What's Possible are trademarks of Waters Corporation. All other trademarks are the property of their respective owners.

© 2007 Waters Corporation. Produced in the U.S.A.  
September 2007 720002329EN AG-PDF

**Waters Corporation**  
34 Maple Street  
Milford, MA 01757 U.S.A.  
T: 1 508 478 2000  
F: 1 508 872 1990  
[www.waters.com](http://www.waters.com)

